1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,710 | 3,050 | 08:49 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.06. | Biohit Oyj: Decisions of the Annual General Meeting of Biohit Oyj | 120 | GlobeNewswire (Europe) | Decisions of the Annual General Meeting of Biohit Oyj
Biohit Oyj Decisions of the Annual General Meeting, June 3, 2026 at 6.00 pm local time (EET)
The Annual General Meeting (AGM) of Biohit Oyj held... ► Artikel lesen | |
| 11.02. | Biohit Oyj: Biohit Group Financial Statement Release 2025 | 201 | GlobeNewswire (Europe) | BIOHIT GROUP FINANCIAL STATEMENT RELEASE 2025 (unaudited)
Biohit Oyj Financial Statement Release 11 February 2026 at 9:30 am local time (EET)
SUMMARY
January-December 2025
Revenue EUR 15.7 million... ► Artikel lesen | |
| BIOHIT Aktie jetzt für 0€ handeln | |||||
| 08.12.25 | Biohit Oyj: New Study Shows Normal GastroPanel Result Safely Rules Out Need for Gastroscopy | 198 | GlobeNewswire (Europe) | Biohit Oyj Press Release8 December 2025 at 10:30 a.m. EEST
New Study Shows Normal GastroPanel® Result Safely Rules Out Need for Gastroscopy
Major Cost Savings Possible
A newly published clinical study... ► Artikel lesen | |
| 12.11.25 | Biohit Oyj: Chile's national cancer prevention strategy brings GastroPanel technology into public healthcare | 312 | GlobeNewswire (Europe) | Biohit Oyj Press Release12 November 2025 at 2:00 p.m. EEST
Chile's national cancer prevention strategy brings GastroPanel® technology into public healthcare
The Chilean Ministry of Health has introduced... ► Artikel lesen | |
| 06.08.25 | Biohit Oyj: Biohit Group Half Year Financial Report 2025 (unaudited) | 269 | GlobeNewswire (Europe) | BIOHIT GROUP HALF YEAR FINANCIAL REPORT 2025 (unaudited)
Biohit Oyj Half Year Financial Report 6 August 2025 at 9:30 am local time (EET)
SUMMARY
January-June 2025
Revenue EUR 7.4 million (EUR 7.4... ► Artikel lesen |
5 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| COGENT BIOSCIENCES | 40,010 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| VERA THERAPEUTICS | 42,960 | 0,00 % | Why Is Vera Therapeutics Stock Gaining Tuesday? | ||
| ERASCA | 18,360 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 324,08 | +0,04 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 3,840 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| TREVI THERAPEUTICS | 19,495 | -0,03 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates | Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 50,91 | -0,02 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| ANNEXON | 6,430 | 0,00 % | Annexon Biosciences: Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones | ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA Tanruprubart MAA Filed in Europe with... ► Artikel lesen | |
| TANGO THERAPEUTICS | 30,120 | 0,00 % | Krebs-Blockbuster-Medikament: Revolution Medicines: Auch Europa will das Medikament so schnell wie möglich! | © Foto: KI-generiert mit DALL-ENach starken Studiendaten aus den USA will nach der FDA auch Europas Arzneimittelbehörde das Medikament so schnell wie möglich zulassen. Revolution Medicines wird immer... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 67,29 | 0,00 % | Kiniksa Pharmaceuticals International, plc (KNSA) Is a Great Choice for 'Trend' Investors, Here's Why | ||
| SEPTERNA | 35,830 | 0,00 % | H.C. Wainwright bestätigt Kaufempfehlung für Septerna Aktie nach Rückschlag bei Konkurrenz | ||
| ABSCI | 11,325 | -0,04 % | Morning Market Movers: Cuprina Holdings, CEA Industries, Absci, The Wendy's Company See Big Swings | MEMPHIS (dpa-AFX) - At 7:10 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 70,59 | +0,06 % | Leerverkäufer-Bericht schickt Tarsus-Aktie auf Talfahrt | ||
| EDGEWISE THERAPEUTICS | 43,160 | +0,07 % | Guggenheim raises Edgewise Therapeutics stock price target on Servier deal | ||
| SANA BIOTECHNOLOGY | 4,120 | 0,00 % | Sana Biotechnology, Inc: Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility | SEATTLE, May 15, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has sold... ► Artikel lesen |
Das Unternehmen BIOHIT OYJ kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 2,880 Euro und damit -0,86 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOHIT OYJ finden Sie auf Wallstreet Online.